Interspecies differences on pharmacokinetics of rebamipide following oral administration to rats and dogs
© 2020 John Wiley & Sons, Ltd..
Rebamipide is used widely in East Asia for the treatment of gastric ulcers, acute gastritis, and exacerbated chronic gastritis. The objective of this study was to investigate the pharmacokinetic (PK) properties of rebamipide following single oral administration in rats and dogs. Eleven rats and dogs received single oral administrations of rebamipide (35 mg/kg and 100 mg, respectively). Blood samples were collected according to the assigned schedule, and the plasma concentration of rebamipide was determined using liquid chromatography-tandem mass spectrometry. A double-peak phenomenon was observed in the PK profile of rebamipide in rats. In contrast, rebamipide showed a conventional PK profile without double peaks in dogs. The half-life of rebamipide in rats (12.85 ± 7.86 h) was longer than that in dogs (5.62 ± 2.24 h), and the apparent total clearance (Clt /F) of rebamipide in rats (3.32 ± 1.18 L/h) was lower than that in dogs (105.01 ± 42.37 L/h). Simple allometric approaches showed that the correlation between body weight and Clt /F (R2 = 0.9287) among rats, dogs, and humans appeared satisfactory. This finding will help not only in understanding the pharmacology of rebamipide but also in establishing a strategy for in vivo evaluation of novel rebamipide formulations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Biopharmaceutics & drug disposition - 41(2020), 6 vom: 30. Juni, Seite 268-272 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baek, In-Hwan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alanine |
|---|
| Anmerkungen: |
Date Completed 09.03.2021 Date Revised 09.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/bdd.2247 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311364349 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311364349 | ||
| 003 | DE-627 | ||
| 005 | 20231225142108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/bdd.2247 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311364349 | ||
| 035 | |a (NLM)32557753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baek, In-Hwan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interspecies differences on pharmacokinetics of rebamipide following oral administration to rats and dogs |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2021 | ||
| 500 | |a Date Revised 09.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons, Ltd. | ||
| 520 | |a Rebamipide is used widely in East Asia for the treatment of gastric ulcers, acute gastritis, and exacerbated chronic gastritis. The objective of this study was to investigate the pharmacokinetic (PK) properties of rebamipide following single oral administration in rats and dogs. Eleven rats and dogs received single oral administrations of rebamipide (35 mg/kg and 100 mg, respectively). Blood samples were collected according to the assigned schedule, and the plasma concentration of rebamipide was determined using liquid chromatography-tandem mass spectrometry. A double-peak phenomenon was observed in the PK profile of rebamipide in rats. In contrast, rebamipide showed a conventional PK profile without double peaks in dogs. The half-life of rebamipide in rats (12.85 ± 7.86 h) was longer than that in dogs (5.62 ± 2.24 h), and the apparent total clearance (Clt /F) of rebamipide in rats (3.32 ± 1.18 L/h) was lower than that in dogs (105.01 ± 42.37 L/h). Simple allometric approaches showed that the correlation between body weight and Clt /F (R2 = 0.9287) among rats, dogs, and humans appeared satisfactory. This finding will help not only in understanding the pharmacology of rebamipide but also in establishing a strategy for in vivo evaluation of novel rebamipide formulations | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a correlation | |
| 650 | 4 | |a double-peak phenomenon | |
| 650 | 4 | |a interspecies | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a rebamipide | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Quinolones |2 NLM | |
| 650 | 7 | |a rebamipide |2 NLM | |
| 650 | 7 | |a LR583V32ZR |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Ha, Dong Kyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Joo, Da-Seul |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min Ji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biopharmaceutics & drug disposition |d 1994 |g 41(2020), 6 vom: 30. Juni, Seite 268-272 |w (DE-627)NLM003938654 |x 1099-081X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2020 |g number:6 |g day:30 |g month:06 |g pages:268-272 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/bdd.2247 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2020 |e 6 |b 30 |c 06 |h 268-272 | ||